VRAX
Income statement / Annual
Last year (2025), Virax Biolabs Group Limited's total revenue was $6.33 K,
a decrease of 95.95% from the previous year.
In 2025, Virax Biolabs Group Limited's net income was -$6.06 M.
See Virax Biolabs Group Limited,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2025
|
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
| Period Ended |
03/31/2025 |
03/31/2024 |
03/31/2023 |
03/31/2022 |
03/31/2021 |
03/31/2020 |
| Operating Revenue |
$6.33 K |
$156.42 K |
$8.56 K |
$0.00 |
$123.82 K |
$99.88 K |
| Cost of Revenue |
$59.40 K
|
$105.83 K
|
$9.93 K
|
$0.00
|
$133.25 K
|
$54.13 K
|
| Gross Profit |
-$53.07 K
|
$50.59 K
|
-$1.37 K
|
$0.00
|
-$9.43 K
|
$45.75 K
|
| Gross Profit Ratio |
-8.38
|
0.32
|
-0.16
|
0
|
-0.08
|
0.46
|
| Research and Development Expenses |
$1.78 M
|
$1.56 M
|
$397.11 K
|
$433.74 K
|
$120.22 K
|
$87.00 K
|
| General & Administrative Expenses |
$4.33 M
|
$4.59 M
|
$5.31 M
|
$1.29 M
|
$457.68 K
|
$602.30 K
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$26.62 K
|
$13.82 K
|
$57.20 K
|
$7.69 K
|
| Selling, General & Administrative Expenses |
$4.33 M
|
$4.59 M
|
$5.33 M
|
$1.30 M
|
$514.88 K
|
$609.99 K
|
| Other Expenses |
$0.00
|
$390.36 K
|
$0.00
|
$0.00
|
$266.00
|
$2.47 K
|
| Operating Expenses |
$6.11 M
|
$6.55 M
|
$5.73 M
|
$1.73 M
|
$635.10 K
|
$696.99 K
|
| Cost And Expenses |
$6.17 M
|
$6.65 M
|
$5.74 M
|
$1.73 M
|
$768.36 K
|
$751.12 K
|
| Interest Income |
$0.00
|
$0.00
|
$0.00
|
$15.44 K
|
$0.00
|
$0.00
|
| Interest Expense |
$58.18 K
|
$26.88 K
|
$15.47 K
|
$15.44 K
|
$28.64 K
|
$90.69 K
|
| Depreciation & Amortization |
$343.39 K
|
$103.10 K
|
$0.00
|
$1.73 M
|
$644.54 K
|
$651.24 K
|
| EBITDA |
-$5.80 M |
-$6.61 M |
-$5.44 M |
-$750.00 |
$0.00 |
$2.47 K |
| EBITDA Ratio |
-916.49
|
-42.25
|
-635.71
|
0
|
0
|
0.02
|
| Operating Income Ratio |
-973.45
|
-41.53
|
-669.64
|
0
|
-5.21
|
-6.52
|
| Total Other Income/Expenses Net |
-$41.00 K
|
-$242.65 K
|
$275.00 K
|
-$16.19 K
|
-$28.38 K
|
-$88.22 K
|
| Income Before Tax |
-$6.20 M
|
-$6.74 M
|
-$5.46 M
|
-$1.75 M
|
-$672.92 K
|
-$739.46 K
|
| Income Before Tax Ratio |
-979.92
|
-43.08
|
-637.51
|
0
|
-5.43
|
-7.4
|
| Income Tax Expense |
-$136.66 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Net Income |
-$6.06 M
|
-$6.73 M
|
-$5.46 M
|
-$1.71 M
|
-$650.98 K
|
-$801.13 K
|
| Net Income Ratio |
-957.39
|
-43.05
|
-637.48
|
0
|
-5.26
|
-8.02
|
| EPS |
-1.96 |
-3.36 |
-5.13 |
-1.5 |
-0.57 |
-0.7 |
| EPS Diluted |
-1.95 |
-3.36 |
-5.13 |
-1.5 |
-0.57 |
-0.7 |
| Weighted Average Shares Out |
$3.10 M
|
$2.01 M
|
$1.06 M
|
$1.14 M
|
$1.14 M
|
$1.14 M
|
| Weighted Average Shares Out Diluted |
$3.10 M
|
$2.01 M
|
$1.06 M
|
$1.14 M
|
$1.14 M
|
$1.14 M
|
| Link |
|
|
|
|
|
|
